Related Experiment Video
Updated: Dec 20, 2025

A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
Dalbavancin for the management of osteomyelitis: a major step forward?
Thamer A Almangour1, Abdullah A Alhifany2
1Department of Clinical Pharmacy, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia.
Abstract:
Osteomyelitis is one of the most challenging infectious diseases to treat and is associated with a significant burden to healthcare systems. There are limited available therapeutic options to treat osteomyelitis caused by Gram-positive pathogens and these are not without limitations. Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms. It demonstrated promising pharmacokinetic/pharmacodynamic properties and safety data to be considered for the treatment of bone infections. However, information on the effectiveness and safety of dalbavancin in the treatment of invasive Gram-positive infections, such as osteomyelitis, is very limited. In this review, we describe the novel characteristics and potential utility of dalbavancin in the treatment of osteomyelitis and summarize its long-term clinical outcomes from published case reports, series and comparative studies.
Insights
Dalbavancin shows promise for treating Gram-positive osteomyelitis, a difficult infection with few options. This review explores its potential and summarizes clinical outcomes for bone infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Orthopedics
Background:
- Osteomyelitis presents significant treatment challenges, especially Gram-positive infections, with limited therapeutic options.
- Dalbavancin, a lipoglycopeptide, is approved for skin infections and shows favorable pharmacokinetic/pharmacodynamic properties for bone infections.
- Current data on dalbavancin's efficacy and safety in osteomyelitis are scarce.
Purpose of the Study:
- To review the characteristics and potential of dalbavancin for treating osteomyelitis.
- To summarize existing clinical outcomes of dalbavancin in bone infections.
Main Methods:
- Literature review of published case reports, series, and comparative studies.
- Analysis of dalbavancin's pharmacokinetic/pharmacodynamic properties and safety profile.
- Evaluation of its utility in treating Gram-positive osteomyelitis.
Main Results:
- Dalbavancin exhibits promising properties for bone infection treatment.
- Limited but emerging clinical data suggest potential effectiveness and safety.
- Further investigation is warranted to establish its role in osteomyelitis management.
Conclusions:
- Dalbavancin represents a potential novel therapeutic option for Gram-positive osteomyelitis.
- Its long-acting nature may offer advantages in managing this complex infection.
- More extensive clinical studies are needed to confirm its role and optimize its use.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Urinary Tract Infection IV: Nursing Management
Endocarditis IV: Nursing Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Endocarditis III: Medical Management
Tonsillitis II: Management

